tibremciclib + fulvestrant

Tibremciclib (BPI-16350) is a novel, potent, and selective small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), structurally similar to abemaciclib but with less inhibition of CDK9. Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and accelerates the degradation of the estrogen receptor. The combination is being developed for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in patients who have progressed on prior endocrine therapy. Clinical studies have shown promising antitumor activity with an objective response rate exceeding 50% in this population[1][3][4][6].

Other names

BPI-16350 + fulvestranttibremciclib + fulvestrant